- Home
- KNSA
as 06-20-2025 4:00pm EST
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
| Founded: | 2015 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 1.9B | IPO Year: | 2018 |
| Target Price: | $38.80 | AVG Volume (30 days): | 707.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.38 - $30.69 | Next Earning Date: | 07-22-2025 |
| Revenue: | $481,166,000 | Revenue Growth: | 59.45% |
| Revenue Growth (this year): | 37.21% | Revenue Growth (next year): | 5.32% |
Stock Insider Trading Activity of Kiniksa Pharmaceuticals Ltd. (KNSA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Jun 16 '25 | Sell | $28.28 | 17,300 | $489,244.00 | 61,563 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Jun 9 '25 | Sell | $30.45 | 70,867 | $2,160,035.40 | 61,563 | |
| Quart Barry D | KNSA | Director | Jun 9 '25 | Sell | $30.34 | 27,448 | $833,001.36 | 12,546 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Jun 3 '25 | Sell | $28.80 | 18,299 | $527,011.20 | 27,009 | |
| Megna Michael R | KNSA | CHIEF ACCOUNTING OFFICER | Jun 3 '25 | Sell | $28.75 | 15,211 | $437,316.25 | 32,546 | |
| Moat Ross | KNSA | CHIEF COMMERCIAL OFFICER | Jun 3 '25 | Sell | $29.02 | 27,594 | $800,777.88 | 9,415 | |
| Patel Sanj K | KNSA | CHAIRMAN & CEO | May 23 '25 | Sell | $27.11 | 86,270 | $2,349,981.45 | 96,674 | |
| Patel Sanj K | KNSA | CHAIRMAN & CEO | May 20 '25 | Sell | $27.02 | 2,349 | $63,469.98 | 96,674 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | May 19 '25 | Sell | $26.41 | 12,000 | $316,920.00 | 61,563 | |
| Patel Sanj K | KNSA | CHAIRMAN & CEO | May 13 '25 | Sell | $27.03 | 2,872 | $77,630.16 | 96,674 |
Latest Kiniksa Pharmaceuticals Ltd. News
KNSA Breaking Stock News: Dive into KNSA Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $2,160,035, According to a Recent SEC Filing
MT Newswires
15 days ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $800,778, According to a Recent SEC Filing
GlobeNewswire
16 days ago
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
GlobeNewswire
23 days ago
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
MT Newswires
2 months ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $2,265,339, According to a Recent SEC Filing
MT Newswires
2 months ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $2,347,335, According to a Recent SEC Filing
Simply Wall St.
2 months ago
3 Stocks Including Kiniksa Pharmaceuticals International That May Be Priced Below Intrinsic Value Estimates
Simply Wall St.
2 months ago
US High Growth Tech Stocks To Watch In April 2025
Compare KNSA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KNSA Kiniksa Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.